We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genomic Signal Processing May Provide Insights into Cancer Treatment

By LabMedica International staff writers
Posted on 22 Dec 2010
A scientist is applying some of the tools of his specialty to try to prod genetic behavior in ways that may cure disease in the near future.

Dr. More...
Dan Schonfeld, professor of electrical and computer engineering at the University of Illinois at Chicago (IL, USA), and a leading expert in image and video analysis, is studying gene expression and interactions in ways that are analogous to the workings of electrical or computer networks. He is project director and lead investigator of a four-year, US$1.2 million National Institutes of Health (Bethesda, MD, USA) grant.

"The idea is that DNA gives expression to proteins, and the amount and level of proteins dictates the state of the organism,” Dr. Schonfeld said.”If the expression level of one DNA goes up, it might reduce the expression level of another. There is this symbiotic relation between the genes in a network and the expression level of each of the proteins depends on one another.”

Dr. Schonfeld envisions this dynamic behavior leading to production of either good or bad proteins. He envisions that using the tools of mathematics and engineering will lead to a way to control this protein production. To achieve this, he and his colleagues model gene regulatory networks as a Markov chain--a statistical modeling tool frequently used in software development. They monitor the network over time and make slight changes or perturbations that may provide a level of control. "We've actually formed a new subarea of inverse perturbation theory where we say we know where we want to go, what is the smallest change in the network that we need to impose in order to guarantee that wherever we are, we're going to end up where we'd like to be,” he said.

Dr. Schonfeld reported that his objective is to take the results of mathematic analysis, convert them into a protocol for making small changes by putting specific chemicals into the cell resulting in a small change in the network, and then monitor its behavior over time to see whether it generates results predicted from the mathematic analysis.

Their hypothetic model will be tested on melanoma cells using RNA interference and plasmid molecules designed to regulate the expression levels of specific genes in a melanoma network. "We need to perturb and affect the influence of one gene on the other in order to move it in a better direction,” he said. "The successful outcome of the proposed approach to the treatment of malignant melanoma cells could serve as a foundation for development of intervention strategies in other cancer networks.”

Dr. Schonfeld noted that an interdisciplinary approach is "essential to an effective plan for developing novel treatment and clinical decision making in cancer research.”

Related Links:

University of Illinois at Chicago



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.